Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) Versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)

About the study

This is a multicenter, two-stage, randomized, controlled, open-label, Phase 3 study comparing the efficacy and safety of iberdomide in combination with dexamethasone and daratumumab (IberDd) versus daratumumab, bortezomib, and dexamethasone (DVd) in participants with relapsed or refractory multiple myeloma (RRMM).

Who can take part

You may be eligible to participate in the study if you meet the following criteria:

INCLUSION CRITERIA

Inclusion Criteria

Documented diagnosis of multiple myeloma (MM) and measurable disease.
Received 1 to 2 prior lines of anti-myeloma therapy.
Must have documented disease progression during or after their last anti-myeloma regimen.
Eastern Cooperative Oncology Group (ECOG) performance status score of 0, 1 or 2.

EXCLUSION CRITERIA

Exclusion Criteria

Any condition that confounds the ability to interpret data from the study.
Has plasma cell leukemia, Waldenstrom's macroglobulinemia or POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, and skin changes), or clinically significant amyloidosis.
Known central nervous system involvement with MM.
Prior therapy with iberdomide.

* Other protocol-defined Inclusion/Exclusion criteria apply.